Efficacy and Safety of E6011, an Anti‐Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double‐Blind, Placebo‐Controlled Phase II Study

OBJECTIVE: To evaluate the efficacy and safety of E6011, a humanized IgG2 monoclonal antibody against human fractalkine (FKN), in a phase II, double‐blind, placebo‐controlled study in rheumatoid arthritis (RA) patients. METHODS: Patients with moderate‐to‐severe RA who had an inadequate response to m...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Yoshiya, Takeuchi, Tsutomu, Yamanaka, Hisashi, Nanki, Toshihiro, Umehara, Hisanori, Yasuda, Nobuyuki, Tago, Fumitoshi, Kitahara, Yasumi, Kawakubo, Makoto, Torii, Kentaro, Hojo, Seiichiro, Kawano, Tetsu, Imai, Toshio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048525/
https://www.ncbi.nlm.nih.gov/pubmed/33038062
http://dx.doi.org/10.1002/art.41555

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048525/
https://www.ncbi.nlm.nih.gov/pubmed/33038062
http://dx.doi.org/10.1002/art.41555

Ejemplares similares